RSH.AX stock trades at A$0.033 pre-market on 21 Mar 2026, presenting a classic oversold bounce setup after a sharp YTD decline. The price sits below the 50-day average (A$0.04) and 200-day average (A$0.05), while volume at 579,396 shares shows below-average liquidity versus a 50-day average of 870,341. Traders should weigh short-term rebound potential against weak fundamentals: EPS is -0.01 and the company carries a negative PE of -3.30. This note outlines the technical trigger, valuation context, catalysts and a plain trade framework for the ASX-listed Respiri Limited (Australia, AUD).
RSH.AX stock: quick snapshot and market context
Respiri Limited (RSH.AX) is listed on the ASX in Australia with a market cap of A$51.98M and 1.58B shares outstanding.
The stock is trading at A$0.033 with a year high of A$0.10 and year low of A$0.021. The Healthcare sector on the ASX has underperformed YTD (-12.02%), with an average PE of 26.60, making RSH.AX structurally smaller and more volatile versus peers. For company filings and product detail see the Respiri site source.
RSH.AX stock: why this looks like an oversold bounce
Price sits below both the 50-day (A$0.04) and 200-day (A$0.05) averages, and YTD performance is down -58.23%, signalling a recent sell-off and oversold condition.
Daily volume of 579,396 is below the average of 870,341, which can magnify short-term moves. A bounce trade would target intraday or multi-day mean reversion rather than a full trend reversal.
RSH.AX stock: financials and valuation snapshot
Fundamentals remain weak: EPS is -0.01, trailing PE is -3.30, price-to-sales is 113.77, and price-to-book is 12.74, reflecting low revenue per share and limited tangible equity.
Operating cash flow per share is -0.0065 and current ratio is 1.18, so liquidity exists but cash generation is negative. These metrics argue for a high-risk, event-driven trade profile rather than long-term value play.
RSH.AX stock: technicals, liquidity and risk metrics
Key technicals show price weakness but potential short-term mean reversion: 50-day average A$0.04, 200-day average A$0.05, year low A$0.021. On-chain technical indicators are mixed; the stock’s low absolute price creates amplified volatility.
Volume and average volume point to thin liquidity (relVolume ~0.67), which raises slippage risk. Use tight sizing and limit orders when trading an oversold bounce.
RSH.AX stock: catalysts, news and timeline
Near-term catalysts include clinical updates, product rollouts for the wheezo device, and any FY earnings commentary; the last earnings announcement timestamp shows 2025-02-25. Material news could flip sentiment quickly for a thinly traded small-cap.
Monitor ASX announcements for RSH (company page) and regulatory notices for rapid news-driven bounces source.
RSH.AX stock: trading plan for an oversold bounce
Trade idea: scale a small position on strength above A$0.035 with stop under A$0.028 and a near-term target at the 50-day average A$0.04; a secondary target is the 200-day average A$0.05. Keep size limited given negative EPS and high price-to-sales.
Risk management: use limit entries, 1%–2% portfolio exposure max, and monitor news flow. For a live dashboard and alerts visit the Meyka RSH.AX page for real-time signals Meyka stock page.
Final Thoughts
RSH.AX stock shows a textbook oversold bounce profile: the share price sits at A$0.033 pre-market on 21 Mar 2026, well below moving averages and after a YTD fall of -58.23%. Short-term traders can target a mean reversion to A$0.04 (50-day) and A$0.05 (200-day), but fundamentals are weak — EPS is -0.01 and valuation ratios (P/S 113.77, P/B 12.74) remain challenging. Meyka AI rates RSH.AX with a score out of 100 at 67.53 (B) — HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst signals and is not investment advice. Meyka AI’s forecast model projects a 12‑month mean price of A$0.07, implying an upside of 112.12% versus the current A$0.033; forecasts are model-based projections and not guarantees. If news or clinical progress arrives, the oversold bounce can accelerate, but traders should keep tight risk controls, small position sizes and watch liquidity closely.
FAQs
Is RSH.AX stock a buy after the oversold drop?
RSH.AX stock shows short-term bounce potential, but fundamentals remain weak (EPS -0.01). Consider small, tactical trades only and use strict stops. This is not financial advice; perform your own research.
What price targets should traders use for RSH.AX stock?
Near-term target is the 50-day average at A$0.04 and a secondary target at the 200-day average A$0.05. Meyka AI’s 12-month model projects A$0.07; forecasts are not guarantees.
How much risk does RSH.AX stock carry for short-term traders?
RSH.AX stock has thin liquidity and amplified volatility. Use small position sizes (1%–2% of portfolio), limit orders and a stop under A$0.028 to manage slippage and downside risk.
Where can I find official RSH.AX announcements and company info?
Official company updates appear on Respiri’s investor pages and ASX announcements. Check Respiri’s site source and the ASX company page for timely disclosures.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)